The Federal Circuit on Friday affirmed a Patent Trial and Appeal Board decision that barred biomedical technology company Illumina from adding amended claims to two DNA sequencing patents, agreeing that the proposed changes were unpatentable.

The appellate court determined that because Illumina Cambridge Ltd. did not demonstrate that the proposed claims were patentable when compared to the prior art, the PTAB correctly barred them, after the board also granted the company’s request to nix its patents’ original claims as part of an inter partes review initiated by Intelligent Bio-Systems Inc., according to the decision.

Intelligent is represented by Robert R. Baron Jr., Marc S. Segal, John L. Cuddihy and Scott David Marty of Ballard Spahr LLP.